Autres langues Alnylam Pharmaceuticals, Inc.

Actions

ALNY

US02043Q1076

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 14/07/2026			Après clôture 02:00:00
281,26 ^USD	-2,36%		286,86	+1,99%

14/07	Les résultats du deuxième trimestre d'Alnylam Pharmaceuticals détermineront les perspectives de revenus pour 2026, selon BofA Securities	MT
14/07	ALNYLAM PHARMACEUTICALS, INC. : BofA Securities à l'achat	ZM

Autres langues

09:30	Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
14/07	Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
09/07	Aktien New York: Nasdaq profitiert von Chip-Aktien - Dow unbewegt
09/07	Aktien New York Ausblick: Dow stabil erwartet trotz neuer Angriffe in Nahost
09/07	AstraZeneca's Wainua fails key heart disease trial, shares tumble
25/06	Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform
25/06	Alnylam Pharmaceuticals Expands Partnership With Komodo to Extend AI Platform Across Enterprise Functions
25/06	US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
22/06	Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
12/06	Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
10/06	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets
04/06	Afternoon Meeting: Aviso para los semiconductores en Wall Street
04/06	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
03/06	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics
03/06	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
03/06	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
27/05	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026
19/05	Alnylam Issues 2025 Corporate Responsibility Report
19/05	Alnylam Pharmaceuticals : 2025 REPORT
13/05	Heart Failure 2026: Neue Datenanalysen belegen robusten und konsistenten klinischen Nutzen von Vutrisiran als Erstlinien-Behandlungsoption für ATTR-CM-Patientenpopulationen – auch bei hoher Krankheitslast
12/05	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients
12/05	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
07/05	Alnylam to Webcast Presentations at Upcoming Investor Conferences
05/05	Alnylam präsentiert auf der „Heart Failure 2026“ neue Analysen, die das konsistente klinische Profil von Vutrisiran bei ATTR-CM unterstreichen
04/05	Alnylam Pharmaceuticals : Q1 2026 Presentation ›